Highlights from EHA – Infographic gallery
Download your copy and discover the core insights from EHA Congress, condensed into a dynamic infographic.
Acute promyelocytic LEUKEMIA (APL)
FIRST RESULTS OF THE APOLLO TRIAL:
A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK APL
Acute lymphoblastic leukemia (ALL)
BLINATUMOMAB FOR FIRST LINE TREATMENT IN INTERMEDIATE AND HIGH RISK DOWN SYNDROME B-CELL ALL: INITIAL FINDINGS FROM THE ALLTOGETHER1 DS TRIAL
PONATINIB VERSUS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ ALL IN THE PHASE 3 PHALLCON TRIAL: IN-DEPTH RESPONDER ANALYSIS
Acute Myeloid Leukemia (AML)
MENIN INHIBITORS
AML Clinical Trials Menin Inhibitor
PHASE 1/2 STUDY OF ORAL DECITABINE/ CEDAZURIDINE WITH VENETOCLAX AND GILTERITINIB IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY AML
COMPLETED DOSE ESCALATION FROM THE FIRST-IN-HUMAN, PHASE 1/2 STUDY OF CD123 NK CELL ENGAGER, SAR443579, IN RELAPSED OR REFRACTORY AML OR HIGH RISK-MYELODYSPLASIA
ADVERSE PROGNOSTIC IMPACT OF SECONDARY-TYPE MUTATIONS IN ELN 2022 FAVORABLE RISK AML